Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act.
Robin C FeldmanPublished in: PLoS medicine (2024)
In this Policy Forum piece, Robin Feldman discusses how current legislation contributes to informational deficits around drug patents for biologic drugs in the United States.